India’s pharmaceutical sector is entering a decisive phase as the government introduces a Minimum Import Price (MIP) on select Active Pharmaceutical Ingredients (APIs) and key intermediates. This policy move, notified by the Director General of Trade Remedies (DGTR), comes in response to long-standing concerns raised by domestic manufacturers regarding predatory pricing practices by Chinese API suppliers. Industry bodies such as the Indian Pharmaceutical Alliance (IPA) have welcomed the decision, calling it a calibrated and transitional measure to reinforce local sourcing and national health security.
Understanding the Rationale Behind Minimum Import Price (MIP)
For over two decades, India has emerged as a global leader in finished pharmaceutical formulations. However, this success has been accompanied by a structural vulnerability—heavy dependence on imported APIs and Key Starting Materials (KSMs), particularly from China. Aggressive price undercutting by overseas suppliers has consistently pressured Indian API manufacturers, eroding margins and discouraging domestic capacity expansion.
The introduction of MIP aims to correct this imbalance. By setting a floor price on specific API imports, the government seeks to prevent unsustainable dumping practices while giving Indian manufacturers a fair opportunity to compete and scale operations.
Lessons from Global Supply Chain Disruptions
The COVID-19 pandemic served as a stark reminder of the risks associated with over-reliance on a single geography for critical pharmaceutical inputs. Supply chain interruptions led to shortages, cost volatility, and operational uncertainty across the healthcare ecosystem. These disruptions strengthened the case for API self-reliance, pushing policymakers to accelerate reforms under the Production Linked Incentive (PLI) scheme.
According to the IPA, the MIP complements the PLI framework by offering short-term protection while domestic API capacity is rebuilt. This dual approach ensures stability without compromising long-term competitiveness.
Impact on Pricing and Patient Access
While the implementation of MIP may result in a marginal rise in raw material costs in the near term, industry experts emphasize that the long-term benefits outweigh the short-term adjustments. A diversified and resilient API ecosystem is critical to safeguarding uninterrupted patient access to essential medicines.
IPA has clarified that price stability and supply security are more sustainable when domestic manufacturing is viable. Dependence on artificially low imports exposes the healthcare system to geopolitical, logistical, and economic risks—factors that can ultimately impact patients far more severely.
Strengthening India’s Domestic Pharma Manufacturing Base
India’s journey from bulk drug manufacturing to formulation dominance has been impressive, but the next phase requires rebalancing the value chain. Reviving domestic API production not only strengthens national health security but also creates opportunities for innovation, employment, and exports.
This shift aligns closely with the broader trend toward monopoly-based product strategies, where companies focus on differentiated, exclusive molecules to improve profitability and market positioning. In this context, India’s evolving API ecosystem supports the growth of a monopoly medicine company in India, enabling manufacturers to control quality, supply, and pricing more effectively.
Role of Contract Manufacturing in the New API Landscape
As API manufacturing regains momentum, collaboration models are also evolving. Many pharmaceutical companies are increasingly partnering with a pharma contract manufacturing company to optimize costs, scale faster, and comply with stringent regulatory standards.
Contract manufacturing plays a pivotal role in translating API self-sufficiency into commercial success. With robust infrastructure, regulatory compliance, and technological expertise, contract manufacturers bridge the gap between policy intent and market execution—particularly for small and mid-sized pharma players.
Addressing Predatory Pricing: A Long-Term Industry Concern
Chinese undercutting in the API market has been a persistent challenge for Indian manufacturers. Prices driven below production cost may offer short-term savings but are economically unsustainable. Once domestic competitors exit the market, monopolistic control often leads to sharp price hikes and supply manipulation.
The MIP directly addresses this issue by neutralizing unfair pricing advantages. As IPA highlighted, this support is essential for Indian pharma companies to remain viable and competitive, especially during the transition phase toward self-reliance.
A Balanced and Forward-Looking Policy Measure
Importantly, the MIP is not positioned as a permanent trade barrier. Instead, it is designed as a temporary, transitional safeguard—allowing Indian manufacturers time to expand capacity, improve efficiencies, and achieve economies of scale. Over time, increased domestic competition is expected to naturally regulate prices and enhance global competitiveness.
Conclusion: Building a Secure and Resilient Pharma Future
The introduction of a minimum import price on select APIs marks a significant policy milestone for India’s pharmaceutical industry. By addressing predatory pricing, encouraging local sourcing, and supporting domestic manufacturing under the PLI framework, the government has laid the foundation for a more resilient and self-reliant healthcare ecosystem.
As India strengthens its API base, integrates advanced contract manufacturing models, and promotes monopoly-driven innovation, it moves closer to securing long-term health sovereignty—ensuring uninterrupted access to affordable, high-quality medicines for both domestic and global markets.